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Ayalew Tefferi,1 Ross L. Levine,2 Hagop Kantarjian3Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic
myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg,
FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions. Other MPN-relevant putative on-
cogenes that are awaiting therapeutic validation, include JAK2 and MPL mutations in polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibrosis (PMF); KITD816Vand other KITmutations in sys-
temic mastocytosis, and FGFR1 rearrangements associated with the 8p11 leukemia/lymphoma syndrome.
The current review focuses on mutant molecules of interest in classic MPNs (ie, CML, PV, ET, and PMF)
in the context of their value as drug targets.
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Pathogenetic breakthroughs in myeloproliferative
neoplasms (MPNs) began in 1960, when Peter Nowell
and David Hungerford discovered the Philadelphia
(Ph) chromosome in chronic myelogenous leukemia
(CML) [1,2]. This historic discovery later led to the
identification of BCR-ABL as the disease-causing mu-
tation in CML [3-5]. On the other hand, the molecular
pathogenesis of the BCR-ABL-negative classic MPNs,
that is, polycythemia vera (PV), essential thrombocy-
themia (ET), and primary myelofibrosis (PMF), re-
mained elusive until 2005, when investigators, led by
D. Gary Gilliland [6], William Vainchenker [7], Radek
Skoda [8], and Anthony Green [9], independently made
the seminal observation that the majority of patients
with classic BCR-ABL-negative MPNs carried a JAK2
gain-of-function (GOF) mutation (JAK2V617F). In
2006, Gary Gilliland’s group, led by Ross Levine, dis-
covered a somatic GOF MPLW515L mutation in
JAK2V617F-negative PMF [10]. In 2007, other JAK2
mutations (exon 12 mutations) in JAK2V617F-negative
patients with PVwere described by AnthonyGreen and1Mayo Clinic, Rochester, Minnesota; 2Memorial Sloan-
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mutations have since been added to the list [12-14].BCR-ABL
The stage for the discovery of BCR-ABL in CML
was set in 1960, when Peter Nowell and David Hun-
gerford described the Ph chromosome [1]. In 1967,
Philip Fialkow and colleagues [15] applied polymor-
phisms in the X-linked glucose-6-phosphate dehydro-
genase (G-6-PD) locus to establish CML as a stem
cell-derived clonal disorder. In 1972, Janet Rowley
[16] clarified the constitution of the Ph chromosome
as a reciprocal translocation between chromosomes 9
and 22; t(9;22)(q34;q11). In 1982, the human homolog
(ABL) of v-abl was mapped to chromosome 9 [17] and
shown to be involved in the Ph translocation [18]. In
1984, the chromosome 22 breakpoint was mapped to
a 5.8-kb area and named the ‘‘breakpoint cluster region
(bcr),’’ which is part of the BCR gene [19,20]. Also in
1984, a new 8.5-kb ABL transcript was described in
CML patients [21,22], and subsequently (1985) identi-
fied as a BCR-ABL fusion transcript [23,24] that trans-
lated to the corresponding P210 fusion protein (1986)
[25]. In 1990, retroviral infection of hematopoietic
stem cells with P210 BCR-ABL was shown to induce
CML-like disease in mice [3-5].
In 1996, Druker and colleagues [26] described the
in vitro, anti-BCR-ABL activity of imatinib mesylate
(IM) [26], a 2-phenylaminopyrimidine class kinase in-
hibitor that targets ABL [27], PDGFR [28], ARG [29],
and KIT [30]; the mechanism of action involves com-
petitive inhibition of the ATP binding site of the ki-
nase [31]. Consequently, orally administered IM has
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tic diseases with mutations involving the aforemen-
tioned kinases: CML [32-38], Ph-positive acute
lymphoblastic leukemia (ALL) [33,39], gastrointesti-
nal stromal tumors (known to harbor KIT or PDGFR
mutations) [40,41], and PDGFR-rearranged MPNs
[42-48].
In newly diagnosed patients with chronic phase
CML (CP-CML), IM is now recommended as the ini-
tial treatment of choice [49]. In the International Ran-
domized Study of Interferon and STI571 (IRIS),
interferon alpha/cytarabine combination was com-
pared with IM in 1106 newly diagnosed CP-CML pa-
tients. The results of this trial were recently updated in
2006 [50]. IMwas found to be superior to combination
chemotherapy in terms of both response rates and pro-
gression-free survival (PFS); the 553 patients initially
assigned to IM therapy had been followed for at least
5 years, and the best observed rates for complete hema-
tologic and cytogenetic remissions were 97% and
82%, respectively. Five-year survival was 89%. IM is
not as effective in advanced phase CML [33] as it is
in CP-CML, and IM-resistant BCR-ABL oncopro-
teins are emerging as an important clinical challenge.
The latter are most often because of acquired ABL
point mutations that usually, but not always (eg,
T315I), remain sensitive to second-generation kinase
inhibitors, including nilotinib and dasatinib [51-56].JAKmutations
Janus kinases (JAKs) are named after the Roman
God with 2 faces because they contain 2 symmetrical
kinase-like domains: the C-terminal JAK homology 1
(JH1) domain possesses tyrosine kinase function,
whereas the immediately adjacent JH2 domain is enzy-
matically inert but is believed to regulate the activity of
JH1 [11,12]. There are 4 JAKs (JAK1, JAK2, JAK3, and
tyrosine kinase 2), and they all contain 7 JH domains
organized into 4 regions; kinase (JH1), pseudokinase
(JH2), FERM (the N-terminal JH7, JH6, JH5, and
part of JH4), and SH2-like (JH3 and part of JH4) [57].
JAK2 fusion mutations
GOF JAK2 fusion mutations have been associated
with T or pre-B ALL, T cell lymphoma, acute myelog-
enous leukemia (AML), and atypical MPN; these in-
clude ETV6-JAK2, t(9;12)(p24;p13), PCM1-JAK2,
t(8;9)(p22;p24), and BCR-JAK2, t(9;22)(p24;q11.2)
[58-64].
JAK2V617F
JAK2V617F is an exon 14 G to T somatic muta-
tion. The nucleotide change at position 1849 results
in the substitution of valine to phenylalanine at codon
617. JAK2V617F was first described in 2005 in pa-
tients with PV, ET, and PMF [6-9]. Subsequently,the mutation has also described in other myeloid neo-
plasms [65,66]. As of the time of this writing,
JAK2V617F has not been reported in lymphoid disor-
ders [67-70], solid tumor [71-73], or secondary myelo-
proliferation [74,75]. In general, mutational frequency
is estimated at over 95% in PV, 50% in ET or PMF,
20% in certain other MPNs including refractory ane-
mia with ringed sideroblasts and thrombocytosis
(RARS-T), and\5% in AML or myelodysplastic syn-
drome (MDS) [76-79].
JAK2V617F induces a PV-like phenotype in mu-
rine transplant models [7,80,81]. However, in a recent
study of JAK2V617F transgenic mice, manipulation of
mutant gene expression resulted in either an ET (lower
expression compared to wild-type allele) or PV pheno-
type with (equal expression) or without (higher expres-
sion) thrombocytosis [82,83]. Current information
regarding mutant allele burden in humans with MPN
partially recapitulates what was seen in the above-men-
tioned experiments with transgenic mice. In other
words, mutant allele burden in patients with ET is sig-
nificantly lower than that seen in patients with either
PV or PMF [84-88]. At least in PV, a higher allele bur-
den is the result of JAK2V617Fhomozygosity, which is
accomplished by mitotic recombination [6,9,89].
However, the interaction between JAK2V617F homo-
zygosity and mutant allele burden, in terms of pheno-
typic determination, is currently not clear [90,91].
In humans, JAK2V617F occurs at a primitive stem
cell level and is chronologically an early event [92-94].
Some, but not all [95], studies have suggested
JAK2V617F clonal involvement of NK [96], T [97],
and B [97] lymphocytes. Regardless, there is evidence
to suggest that JAK2V617F may not be the initial clo-
nogenic event in either PV or otherMPNs, and that its
presence might not be mandatory for endogenous col-
ony formation [98-100]. The recent demonstration of
JAK2V617F-negative leukemia clones arising in
JAK2V617F-positive MPN patients lends further sup-
port in this regard [101,102]. On the other hands,
JAK2V617F or other JAK2mutations might be a nec-
essary component of the PV phenotype because they
are detected in all patients with the disease [13]. Fur-
thermore, recent studies suggest that germline genetic
variation [103] and/or the occurrence of other con-
comitant mutations [12] might explain why the same
mutation is present in apparently different disease phe-
notypes.
JAK2 exon 12 mutations
In 2007, JAK2 exon 12 mutations were described
in JAK2V617F-negative patients with PV in whom er-
ythrocytosis was the predominant feature [104]. Be-
cause of the latter feature, some of the cases were
assigned the diagnosis of ‘‘idiopathic’’ erythrocytosis,
although their serum Epo level was almost always be-
low the reference range and EECs were demonstrated
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alleles induce cytokine-independent/hypersensitive
proliferation in erythropoietin receptor-expressing
cell lines and constitutive activation of JAK-STAT
signaling [104]. In addition, 1 of these mutations
(JAK2K539L) induced a PV phenotype in a mouse
transplant model. Unlike the case with PV-associated
JAK2V617F, exon 12 JAK2 mutations were heterozy-
gous but associated with stronger abnormal JAK2 acti-
vation.
Many other studies have now confirmed the obser-
vations from the above-mentioned study [13,105-109],
and in the process, most [13,105,106]. but not all
[107,109], of the studies suggested that exon 12 muta-
tions occurred in virtually all JAK2V617F-negative
PV cases (ie, approximately 3% of all PV cases).
Among all currently described exon 12 mutations,
the most frequent was N542-E543del, comprising 17
of 52 cases reported at the time of the latest report
[107]. In general, many JAK2 exon 12 mutation-posi-
tive patients present with apparently ‘‘isolated’’ eryth-
rocytosis, but because of their association with
subnormal serum Epo level and the presence of
EECs, they fulfill the 2008 WHO diagnostic criteria
for PV [110].MPL mutations
MPL (myeloproliferative leukemia virus oncogene
homolog) belongs to the hematopoietin receptor super-
family, and enables its ligand, thrombopoietin (Tpo), to
facilitate both global hematopoiesis (early expansion of
differentiating clones) and megakaryocyte growth and
differentiation [111-113]. Germline MPL mutations
have been associated with either familial thrombocyto-
sis (GOF transmembrane domain mutation; S505N)
[114] or congenital amegakaryocytic thrombocytopenia
(LOF mutations) that often progresses to aplastic ane-
mia [115-117]. In 2006, a somatic GOF MPLW515L
mutation (a G-to-T transition at nucleotide 1544 re-
sulting in a tryptophan to leucine substitution at codon
515 of the transmembrane region) was described in
JAK2V617F-negative PMF [10]. Subsequently, an ad-
ditional MPL mutation involving the same 515 codon
(MPLW515K) was incidentally discovered during
screening for MPLW515L, and the prevalence of
both mutations was determined at approximately 5%
in PMF and 1% in ET [118]. More recent studies
have identified other somaticMPLmutations including
MPLW515S andMPLS505N (mentioned above in as-
sociation with familial thrombocytosis) and higher
prevalence rates: approximately 4% in ET (9% in
JAK2V617F-negative cases) and up to 11% in PMF
[119-122]. As is the case with JAK2V617F, MPL515
mutations are early, stem cell-derived events involving
both myeloid and lymphoid progenitors [123-126]
andMPLW515Lhas been shown to transform cell linesin terms of both cytokine-independent growth andTpo
hypersensitivity, activate JAK-STAT/ERK/Akt, and
induce PMF-like disease in mice that is characterized
by a rapid fatal course, marked thrombocytosis, leuko-
cytosis, hepatosplenomegaly, and bonemarrow fibrosis
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